Suchergebnisse - "Motoi, Noriko"

PubPharm (10)

1

STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer

enthalten in: Anticancer research | 2024

von Fuchizawa, H. | Ando, K. | Motoi, N. | +10

2

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

enthalten in: Cancer immunology, immunotherapy : CII | 2022

von Jo, H. | Yoshida, T. | Horinouchi, H. | +9

3

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma

enthalten in: Clinical lung cancer | 2021

von Shirasawa, M. | Yoshida, T. | Takayanagi, D. | +16

4

Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC

enthalten in: Clinical lung cancer | 2021

von Takeyasu, Y. | Yoshida, T. | Shibaki, R. | +7

5

Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%) : A case series

enthalten in: Thoracic cancer | 2020

von Inaba-Higashiyama, R. | Yoshida, T. | Jo, H. | +3

6

Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab : a single-institution retrospective study

enthalten in: Melanoma research | 2020

von Namikawa, K. | Takahashi, A. | Mori, T. | +9

7

A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2019

von Naito, T. | Udagawa, H. | Sato, J. | +15

8

Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden : A case report

enthalten in: Thoracic cancer | 2019

von Naito, T. | Umemura, S. | Nakamura, H. | +11

9

Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease

enthalten in: Medical oncology (Northwood, London, England) | 2019

von Shibaki, R. | Murakami, S. | Matsumoto, Y. | +9

10

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer

enthalten in: Thoracic cancer | 2019

von Shibaki, R. | Murakami, S. | Shinno, Y. | +8

1
[1]